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Abstract
Background: Non-medical/illegal use of prescription stimulants popularly have been referred to
as "study drugs". This paper discusses the current prevalence and consequences of misuse of these
drugs and implications of this information for drug policy.
Results: Study drugs are being misused annually by approximately 4% of older teens and emerging
adults. Yet, there are numerous consequences of misuse of prescription stimulants including
addiction, negative reactions to high dosages, and medical complications. Policy implications include
continuing to limit access to study drugs, finding more safe prescription drug alternatives,
interdiction, and public education.
Conclusion: Much more work is needed on prescription stimulant misuse assessment, identifying
the extent of the social and economic costs of misuse, monitoring and reducing access, and
developing prevention and cessation education efforts.
Prescription stimulants that have been used non-medi-
cally/illegally often have been referred to as "study drugs"
or "cramming drugs," and sometimes "kiddy coke." Meth-
ylphenidate (e.g., Ritalin) is the most widely misused and
researched of these drugs and has been referred to as "Vita-
min R", "Skippy", "the Smart Drug", "Smarties", "Poor
Man's Cocaine", "West Coast", and "R Ball" [1-4]. While
prescribed for sufferers of Attention-Deficit/Hyperactivity
Disorder (ADHD), and costing approximately $0.50 a pill
when obtained licitly, prescription stimulant pills can cost
$3 to $15 each when sold illicitly [1-3,5]. Several recent
news articles have been published about potential dan-
gers of misuse of study drugs, and in February 2006, a
Food and Drug Administration advisory panel urged that
the strongest possible safety warning (the "black box"
warning for cardiac problems and sudden death in pediat-
ric patients) be used on these drugs [6,7]. This review will
describe briefly the history of prescription stimulants,
their prevalence of misuse among emerging adults [8],
and potential negative consequences. Policy implications
also will be suggested.
Brief history and current status of study drugs
Methylphenidate was first created in 1944 as part of a
search for a non-addictive stimulant, and it was suggested
as a means of regulating children's behavior in 1963, to
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control "hyperkinesis" [9]. Eventually such problematic
behavior among children became labeled as "Attention-
Deficit/Hyperactivity Disorder" (ADHD; [10]). ADHD
refers to a constellation of dysfunctions that hinder atten-
tion regulation, motor behavior, impulsivity, emotional
expression, and planning [11].
By 1970, 15 different pharmaceutical companies manu-
factured over 30 kinds of prescription stimulant-type
products. Eventually a very large ADHD drug market
developed, which has been dominated by stimulants.
These currently include methylphenidate (brand names:
Ritalin, Ritalin SR, Methylin, Methylin ER, Metadate,
Metadate ER, Concerta), demethylphenidate (brand
name: Focalin) and amphetamine preparations including
D-amphetamine (brand names: Dexedrine, Spansule,
Dextrostat), methamphetamine (brand name: Desoxyn)
and D, L-amphetamine (brand names: Adderall, Adderall
XL). People have observed the misuse of study drugs
among those not diagnosed with ADHD, particularly
among emerging adults [12]. "Emerging adulthood" is a
recently "coined" developmental period, referring to
young people 18–25 years of age, who bridge the gap
between adolescence and young adulthood [8]. Misuse
has been observed particularly in college settings [12,13].
Many misuse these drugs to help keep alert and concen-
trate as they prepare ("cram") for tests or complete term
papers (though, of course, people may misuse them for a
variety of reasons [12,13])--hence the term "study drugs"
[14].
Prevalence of non-medical use of prescription 
stimulants: college settings
Regarding college prevalence data and policy, the most
frequently studied prescription stimulant is methylpheni-
date. From 1990 to 2000, use of methylphenidate
increased five-fold in the United States, which consumes
approximately 90% of all methylphenidate [12,15]. The
Monitoring the Future research group has been studying
the annual prevalence of use of methylphenidate (meas-
ured as "Ritalin," as a stand-alone question) among teens
and emerging adults since 2001 [[16]; also see [17]]. The
annual prevalence among 8th, 10th, and 12th graders has
averaged 2.7%, 4.3%, and 4.5%, respectively, over the
period from 2001 to 2004. Its use among college students
has averaged 5.0% over this period, whereas its use among
non-college emerging adults has averaged approximately
2.9% over this period. (About 25% of these users use
methylphenidate about once a month [16,17].)
Its use remains at approximately 3.5% through 24 years
age. At 25 years of age its use decreases to 1.5% and then
below 1% at 29–30 years of age [16]. Thus, use of this
study drug appears to peak from the ages of 16 to 24 years
of age (older adolescence through emerging adulthood),
following the same course of use prevalence as other drugs
such as alcohol and illicit drugs [also see [18]]. Males are
relatively likely to use methylphenidate (3.7% versus
1.6%), and use appears slightly higher in the southern
states in the Monitoring the Future survey (2.8% versus
2.0–2.5%), and in very large urban areas (about 3.0% ver-
sus 1.9–2.7%). Methylphenidate appears most likely to be
used by male college students in large cities [16].
Several studies have been completed to discern prevalence
and reasons for non-medical use of prescription stimu-
lants. Simoni-Wastila & Strickler [19] examined 1991–
1993 data from the National Household survey on Drug
Abuse (NHSDA), a nationally representative, rand-
omized-block selected household sample of 12-year olds
and older. They found that 1% of the U.S. population had
used prescription stimulants non-medically in the past
year, and a fifth of them reported problem use (e.g., ina-
bility to cut down use), though they failed to find signifi-
cant demographic, health status, or drug use correlates of
illicit problem stimulant use. Certainly, the age range of
highest lifetime use of prescription stimulants is from 18–
25 [20], approximately 5%, and at least doubling percent-
age figures among other age categories viewed across mul-
tiple years of this survey.
In a more recent study, McCabe and colleagues [12] exam-
ined the prevalence rates and correlates of non-medical
use of prescription stimulants (methylphenidate, D-
amphetamine, or D,L-amphetamine) among U.S. college
students. One hundred and nineteen nationally represent-
ative 4-year colleges in the United States were selected and
a sample of 10,904 randomly selected college students in
2001 were examined via self-report surveys. The life-time
prevalence of non-medical prescription stimulant use was
6.9%, past year prevalence was 4.1% (but ranged from 0%
to 25% across colleges), and past month prevalence was
2.1%. A total of 5.8% of males and 2.9% of females
reported annual use of non-prescribed stimulants. In
addition, 2.8% of males (1.6% of females) reported use in
the past month. Whites were relatively likely to misuse
prescription stimulants compared to African American,
Asian, or other groups (annual use: 4.9% versus 1.6%,
1.3%, and 3.1%, respectively). The prevalence of non-
medical use of prescription stimulants among students
attending historically African American colleges and uni-
versities was low [12].
Past year rates of non-medical use ranged from zero to
25% at individual colleges. Non-medical use was higher
among college students who were members of fraternities
and sororities (annual use: 13.3% if living in a fraternity
or sorority house, 3.5%-4.5% otherwise; 8.0% versus
1.8%–2.5% last month use), and earned lower grade
point averages (annual use: B or lower average, 5.2%; B+Substance Abuse Treatment, Prevention, and Policy 2006, 1:15 http://www.substanceabusepolicy.com/content/1/1/15
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or higher, 3.3%). Rates were higher at colleges located in
the north-eastern region of the U.S. (6.3% annual use),
and southern region (4.6%), then other regions (2.8–
3.2%), and colleges with more competitive admission
standards (5.9% versus 1.3–4.5% annual use). Non-med-
ical prescription stimulant users were more likely to report
use of alcohol, cigarettes, marijuana, ecstasy, and cocaine,
raising the possibility that use of prescription stimulants
for non-medical purposes may be related as much to an
addiction disorder as to an aid to study.
These studies examined a variety of prescription stimulant
drugs, not just methylphenidate. Thus, arguably, a 4.1–
5.4% annual prevalence represents the most accurate
statement regarding those at highest prevalence of non-
prescription use.
Several single-university sample surveys of college stu-
dents have reported a range of use reports. Massachusetts,
Michigan, New Hampshire, Maine, Florida, Pennsylvania,
Wisconsin, and Texas samples are reported herein. In one
random sample at a Massachusetts college of liberal arts
(n = 283), 16.6% of the sample reported having taken
methylphenidate for fun (non-medical purposes), and
12.7% reported having snorted methylphenidate; a
majority of the self-reported users were under 24 years of
age [21].
Teter, McCabe and colleagues [22] administered a survey
to 2250 randomly selected undergraduates at the Univer-
sity of Michigan (in 2001) and found a 3% annual preva-
lence of illicit methylphenidate use, which was positively
associated with other licit and illicit drug use (but not
with gender or ethnicity). The same research group [23]
assessed the prevalence and motives for illicit use of pre-
scription stimulants (methylphenidate [two brands], D-
amphetamine, and D, L-amphetamine) to a random sam-
ple of 9,161 undergraduate college students at the Univer-
sity of Michigan (surveyed in 2003). Of the study
participants, 8.1% reported lifetime and 5.4% reported
past-year illicit use of prescription stimulants. The most
prevalent motives given for illicit use of prescription stim-
ulants were to (1) help with concentration (58% of life-
time illicit users), (2) increase alertness (43%), and (3)
provide a high (43%). Eighty-six percent reported not
being prescribed these drugs in their lifetime. Men were
more likely than women to report illicit use of prescrip-
tion stimulants (9.3% versus 7.2%), and Whites and His-
panics (9.5% and 8.9%, respectively) were more likely to
use them than African American or Asian students (2.7%
and 4.9%, respectively). Illicit use of prescription stimu-
lants was associated with elevated rates of alcohol and
other drug use, and total number of motives endorsed and
alcohol and other drug use were positively associated.
These same authors [13] reported an additional study of
prescription drug misuse and diversion (i.e., diverting use
from those prescribed the medication to those not pre-
scribed the medication), in the same cohort as the Teter et
al. [23] study. The annual illicit use of stimulant medica-
tion was 5%, and the illicit use-medical use ratio for stim-
ulant medication (overall = 2.45) was the highest among
the four classes of prescription drugs examined (overall
ratios for the other three drug types, sleeping, sedative/
anxiety, and pain medications were less than 1.0). Medi-
cal users of stimulants for attention deficit hyperactivity
disorder were the most likely to be approached to divert
their medication (54% of them reported being
approached to sell, trade, or give away their medication).
Illicit users of medical stimulants were relatively likely to
use other drugs (odds ratios varied from 6.00 for binge
drinking to 21.25 for annual cocaine use).
White, Becker-Blease, & Grace-Bishop [5] examined illicit
use of stimulant medication among undergraduate and
graduate students at the University of New Hampshire. Of
1,025 randomly sampled participants, 16% reported mis-
using stimulant medication (96% of those that specified a
medication preferred to misuse methylphenidate, 2%
misused D, L-amphetamine). Ninety-percent of these sub-
jects reported never receiving an ADHD diagnosis. Results
failed to differ as a function of gender. Most used pill form
(55%), but 40% had used intranasally. Of those that mis-
used prescription stimulants, about 50% reported misuse
2–3 per year, whereas the other 50% reported misuse at
least once per month. Reasons for misusing prescription
stimulant medication (i.e., illegal use) included improv-
ing attention, partying, reducing hyperactivity, and
improving grades.
In a convenience sample survey of 150 undergraduates at
a small U.S. college (in Maine), 35.5% took prescription
amphetamines (D,L-amphetamine, methylphenidate, or
D-amphetamine) illegally. A total of 24% of the illicit
users used amphetamines to study, but 19.3% used them
in combination with alcohol for recreational reasons [24].
There have been several unpublished surveys conducted
by individual colleges. For example, Kapner [1] summa-
rized four unpublished surveys of methylphenidate use
from college reports, and found that 1.5% of students sur-
veyed at the University of Florida in 2002 reported using
methylphenidate recreationally in the last 30 days, 9% of
those undergraduates surveyed at the University of Penn-
sylvania in 2000 had used someone else's ADHD prescrip-
tion medication, 20% of those students surveyed at the
University of Wisconsin, Madison, in 1998, had illegally
taken an ADHD medication at least once, and 2% and
1.5% of those students surveyed at the University of Texas
in 1997 had used methylphenidate illegally in their life-Substance Abuse Treatment, Prevention, and Policy 2006, 1:15 http://www.substanceabusepolicy.com/content/1/1/15
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times and the past year, respectively. The sampling details
of these reports were not disclosed and could not be
located; thus, these results must be taken with caution. In
the studies involving college students, college student par-
ticipation rates among those "randomly" selected varied
from 20–60%. Thus, replication studies with recruitment
of a greater percentage of the targeted sample still are
needed, if this can be accomplished in college settings.
To summarize, lifetime, past year, and past month illicit
use of prescription stimulants among emerging adults
appears to vary widely while averaging approximately 7%,
4%, and 2%, nationally. Use is most prevalent among
white or Hispanic male college students, who are associ-
ated with fraternities, struggling with their grades, and
who generally live in larger urban areas (though not
always) in northeastern or southern regions of the U.S.
These youth also tend to use other drugs particularly can-
nabis, alcohol, MDMA, and cocaine [also see [25]]. They
use study drugs to enhance their study and social life, and
sometimes to stay awake while using another drug such as
alcohol.
Routes of Administration
Prescription stimulants have been misused through oral,
intranasal, and intravenous routes of administration. Oral
misuse of prescription stimulants results in noticeable
symptoms if taken in high doses. Encapsulated extended-
release formulas can be misused and abused as well as the
older shorter-release formulas by breaking open a capsule
and snorting the contents. A series of case studies have
indicated intranasal and injection abuse of study drugs
[4,26,27]. In one study of New Hampshire undergraduate
and graduate students [5], the preferred method of use
among study drug misusers was oral (55%), intranasal
(40%), and "Other" (4%). The route of administration of
the "other" category was not specified, but it is possible
that intravenous use was being referred to. More discon-
certing, 79% of illicit users were not at all concerned
about using these study drugs.
Potential negative consequences of "study drug" 
use
There are three general potential negative consequences of
misusing study drugs. These include: (a) potential for
addiction, (b) potential for reactions to high doses, (c)
and potential for medical complications. These three con-
sequences are discussed next.
Addiction
A review of 60 studies suggested that the reinforcing or
subjective effects of methylphenidate (in 80% of these
studies) functions similarly to d-amphetamine or cocaine
(i.e., as a reinforcer, in drug discrimination substitution,
and subjective effects such as producing a "high" or
"rush"), and that there is definite abuse potential [4]. Tol-
erance develops and characteristic stimulant withdrawal
symptoms have been reported including fatigue or
exhaustion, depression, unpleasant and vivid dreams,
insomnia or hypersomnia, increased appetite, psychomo-
tor retardation or agitation, or irritability [2,11,26-28].
Similar effects may be expected with all prescription stim-
ulants.
Stimulants tend to increase or augment dopaminergic
(reward, anticipation) and serotoninergic (self-adminis-
tration initiation, maintenance of pleasure) neurotrans-
mission [29]. Methylphenidate appears to work by
blocking pre-synaptic dopaminergic transporters [29],
and does not appear to affect the serotonergic system [30].
Its effects on dopaminergic transmission are similar to
cocaine, and may lead to similar consequences through
intranasal administration or injection. For example, in 23
case studies of intravenous methylphenidate use, the pat-
tern of withdrawal and toxicity symptoms were similar to
that of cocaine and amphetamine [26,27].
Oral use produces its effect in approximately an hour
compared to a couple of minutes for other routes of meth-
ylphenidate (or cocaine) administration. Oral intake does
not produce nearly as much reinforcing effect and, hence,
has much less abuse potential [31], depending on the
dose taken. Still, one should not stop using oral methyl-
phenidate abruptly if one has been using it consistently,
because it will produce withdrawal symptoms characteris-
tic of other stimulants [2,11,18]. Much more work is
needed on the study of how routes of administration may
interface with misuse and addiction to prescription stim-
ulants.
High doses
At high doses, study drugs can produce symptoms such as
emotional lability, anxiety, twitchiness, aggressiveness,
loss of appetite, confusion, dizziness or blurred vision,
insomnia, headaches, sweating, and dryness of the mouth
and eyes [5,11,26]. Methylphenidate and other study drug
misuse may result in formification hallucinations (e.g.,
one may have a tactile perception as if there are bugs
under ones skin), repetitive behaviors ("tweaking"), and
bizarre delusions (e.g., personalization of objects, para-
noia) [1,11,21], if used chronically at high doses, espe-
cially by intranasal administration or injection.
In 1990, there were about 271 emergency room reports
involving methylphenidate, 1,727 in 1998, and 1,478 in
2001 [32]. The total number of emergency department
visits resulting from use of all psychotherapeutic CNS
stimulants was 4091 in 1998, 3644 in 1999, 3336, inSubstance Abuse Treatment, Prevention, and Policy 2006, 1:15 http://www.substanceabusepolicy.com/content/1/1/15
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2000, 3146 in 2001 and 3275 in 2002 [33]. There are
approximately 25 emergency room deaths per year among
up to 3 million users of prescription stimulant drugs
(including both those medically prescribed and not pre-
scribed these drugs). Thus, the likelihood of dying from
such drugs appears to be approximately 1 in 120,000 [32].
Medical complications
Most study drugs raise blood pressure and may place users
at risk for heart attacks and stroke [5,6]. For example, side
effects may include irregular heartbeat and very high
blood pressure [1,15]. Thus, use is contraindicated if one
has a history of high blood pressure or other cardiovascu-
lar-related concerns. In addition, use is contraindicated
among those suffering from psychiatric conditions
including severe anxiety, glaucoma, motor tics (or
Tourette's syndrome), psychotic conditions, depression, a
seizure disorder, or a history of drug abuse. Also, one
should not use prescription stimulants if one has experi-
enced a narrowing of ones gastrointestinal tract or a dam-
aged liver. Finally, use also is contraindicated if one is
taking other prescribed drugs particularly monoamine
oxidase (MAO) inhibitors [e.g., see [2,34]].
Intravenous use of prescription stimulants is particularly
dangerous. In particular, intravenous (IV) abuse of meth-
ylphenidate may result in talcosis. Talcosis is a reaction to
talc, a filler and lubricant in methylphenidate and other
oral medication. This inflammation reaction occurs in the
lungs and related consequences include lower lobe panac-
inar emphysema [35].
Implications for policy change
Current rates of study drug misuse show the potential to
increase dramatically in direct proportion to the preva-
lence of manufacture, prescription, and general availabil-
ity [36]. Five types of policy change are recommended to
curb the misuse of these drugs.
First, limiting access to prescription stimulants may be a
very important approach [36]. Those who are correctly
prescribed ADHD medications could be involved in a
monitoring system to try to make sure that they are not
serving as suppliers to others [12,23]. Fortunately, 21
states in the U.S. use some sort of prescription monitoring
program (PMP) to monitor the use of abuse-able prescrip-
tion drugs [37]. All these states include Schedule II stimu-
lants as one of the drug categories being monitored and,
often, lower scheduled ones as well.
Second, facilitating development of more safe alternative
types of drugs may be very important as well [36]. There is
a relatively novel drug, Lilly's atomoxetine (brand name:
Strattera), which has the advantage of not being classed as
a central nervous system stimulant. Atomoxetine is a
norepinephrine transporter inhibitor. It has similar side
effects as the other drugs as well as potentially leading to
urinary hesitation or retention. However, it probably has
less abuse potential [11]. There also exist novel pharma-
ceutical delivery systems that have been shown to be less
prone to abuse (e.g., the Concerta formulation of methyl-
phenidate [13]). Possibly, use of these types of prescrip-
tion drugs by those suffering from ADHD may lead to
decreased prevalence of prescription drug misuse through
diversion to those not suffering from ADHD. A recent
study indicates very little misuse of the extended-release
formula of methylphenidate in 2002 [18].
The third change pertains to policies aimed at interdic-
tion. These policies would be enforced by local law
enforcement personnel to disrupt unauthorized points-
of-sale or distribution. However, according to an article by
Pentz and colleagues based on a review of interdiction
policies aimed at other drugs, this type of policy has
appeared to be largely ineffective [36].
The fourth is policies aimed at warning the public as well
as users about the negative consequences of illicit use of
prescription stimulants (study drugs). The FDA while hav-
ing declared most of these drugs as controlled substances,
should provide a wider array and more visible platforms
(e.g., on labels, public announcements) discouraging mis-
use and highlighting negative consequences of use, unau-
thorized sales, and distribution of these drugs.
The fifth, and perhaps the most promising, are policies
aimed at institutionalization of education about study
drugs. Education could include changes in physician treat-
ment regimen protocols that are formalized by the AMA,
including requirements for additional continuing educa-
tion for pediatricians and family physicians to learn about
non-medical treatment options and the potential for
diversion of these medications. Potential for diversion
also should be instructed to medication users. As men-
tioned earlier in this review, at least one study has exam-
ined the prevalence rates of prescribed college stimulant
users being approached to divert their stimulant medica-
tion [13]. Of the undergraduate students who were medi-
cally prescribed stimulant medication for ADHD,
approximately 54% had been approached to divert their
medication (e.g. sell, trade or give away) in the past year.
Means to protect these students from those that might lure
or coerce them into providing their stimulant medication
to others are needed. Possibly, college-level prevention
programs could be developed to include resistance to
offers of study drugs other than those prescribed by a phy-
sician. One recommendation that has been made in the
New York University Health Center is that those persons
prescribed ADHD drugs while in college should keep their
drug in a private location, and give reasons for not provid-Substance Abuse Treatment, Prevention, and Policy 2006, 1:15 http://www.substanceabusepolicy.com/content/1/1/15
Page 6 of 7
(page number not for citation purposes)
ing the drugs to others (e.g., to avoid a potential allergic
reaction, not enough to share, claim that one has stopped
using the drug; [38])
Instruction in good study skills is one way to try to bypass
reliance on cramming for exams and associated prescrip-
tion medication diversion. There are a variety of self-help
courses that universities provide to help improve study
skills (e.g., at Virginia Polytechnic Institute [39]). These
skills involve time management (e.g., scheduling classes
and study times, keeping track of tasks to be completed
[task lists, charting work tasks on a timeline]), placing a
priority on studying (treating it as a full-time job), identi-
fying and removing time wasters, and learning how to
concentrate better (e.g., removing distractions from envi-
ronment, studying in fixed locations, using a timer to
increase concentration time, taking scheduled breaks).
Cognitive-behavior therapy is popularly suggested for
treatment of study drug abuse, but little empirical data
exists specifically on its use with these drugs [e.g., [26]].
Conclusion
"Study drug" misuse deserves more study. It appears to be
concentrated in certain groups for whom programming
might be tailored (e.g., males who abide by a fraternity
college lifestyle, persons with friends or associates who are
prescribed the medication). Abuse occurs when used in
rather high doses (orally) or when administered
intransally or injected. Monitoring its spread among at
risk populations is important. Aggressive marketing of
study habit courses is needed. Youth that illegally use
these prescription stimulant drugs are relatively likely to
use other drugs and suffer from drug abuse [23,25]. They
are also relatively likely to incur serious damage from
improper administration of these drugs. Strong warning
labels may help, but may be limited as a means of drug
control [25,36]. Much more work is needed on prescrip-
tion stimulant misuse assessment, reducing access, pre-
vention, cessation, and on identifying the social and




The author(s) declare that they have no competing inter-
ests.
Authors' contributions
SS did the reference search and the majority of the writing
and editing.
MAP contributed most of the policy material and editing.
D A-M contributed some of the material on prescription
stimulant consequences and editing.
TM, as an experienced writer on Ritalin abuse, provided a
mentor role, contributed to material throughout, and
editing.
Acknowledgements
This research was supported by grants from the National Institute on Drug 
Abuse (DA07601, DA13814, DA 16090, and DA16094) held by Dr Suss-
man.
References
1. Kapner DA: Recreational use of Ritalin on college campuses Newton,
Massachusetts: The Higher Education Center for Alcohol and Other
Drug Prevention; 2003. 
2. Klein-Schwartz W: Abuse and toxicity of methyphenidate.  Curr
Opin Pediatr 2002, 14:219-223.
3. National Drug Intelligence Center  Ritalin fast facts 2003 [http://
www.usdoj.gov/ndic/pubs6/6444/index.htm]. Washington, D.C.: U.S.
Department of Justice
4. Kollins SH, MacDonald EK, Rush CR: Assessing the abuse poten-
tial of methylphenidate in nonhuman and human subjects: A
review.  Pharmacol Biochem Behav 2001, 68:611-627.
5. White BP, Becker-Blease KA, Grace-Bishop K: Stimulant medica-
tion use, misuse, and abuse in an undergraduate and gradu-
ate student sample.  J Am Coll Health 2006, 54:261-268.
6. Alonso-Zaldivar R: Warning urged for ADHD drugs: An FDA panel cites
heart risks in its advisory on Methylphenidate and similar medications Los
Angeles Times February 10, The Nation section; 2006. 
7. Phelan K, Johan-Liang R: Memorandum: Adverse events
reported with immediate-release mixed amphetamine salt
products during the Adderall XR 1-year post-pediatric exclu-
sivity period.  In Department of Health and Human Services, Public
Health Service, Food and Drug Administration February 6 Washington,
D.C.:, Center for Drug Evaluation and Research [ODS PID#
D060042]; 2006. 
8. Arnett JJ: Emerging adulthood: A theory of development from
the late teens through the twenties.  Am Psychol 2000,
55:469-480.
9. Freedman AM, Kaplan HI, Sadock BJ: Modern synopsis of psychiatry/II
Baltimore, Maryland: The Williams & Wilkins Co; 1976. 
10. American Psychiatric Association: Diagnostic and statistical manual of
mental disorders (DSM-IV-TR) Washington, DC:American Psychiatric
Association; 2000. 
11. Braun DL, Dulit RA, Adler DA, Berlant J, Dixon L, Fornari V, Goldman
B, Hermann R, Siris SG, Sonis WA, Richter D: Attention-Deficit/
Hyperactivity Disorder in adults: Clinical information for pri-
mary care physicians.  Prim Psychiatry 2004, 11:56-65.
12. McCabe SE, Knight JR, Teter CJ, Wechsler H: Non-medical use of
prescription stimulants among US college students: preva-
lence and correlates from a national survey.  Addiction 2005,
100:96-106.
13. McCabe SE, Teter CJ, Boyd CJ: Medical use, illicit use and diver-
sion of abusable prescription drugs.  J Am Coll Health 2006,
54:269-278.
14. Safer DJ: Are stimulants overprescribed for youths with
ADHD?  Ann Clin Psychiatry 2000, 12:55-62.
15. Schetchikova NV: Children with ADHD: Medical vs. chiroprac-
tic perspective and theory.  J Am Chiroprac Assoc 2002:28-38.
16. Johnston LD, O'Malley PM, Bachman JG, Schulenberg JE: Monitoring
the Future national survey results on drug use, 1975–2004.  In
Volumes I and II: Secondary school students and College students & adults
ages 19–45 Bethesda, MD: National Institute on Drug Abuse (NIH
Publication Nos. 04–5727 and 05–5728); 2005. 
17. McCabe SE, Teter CJ, Boyd CJ, Guthrie SK: Prevalences and cor-
relates of illicit methylphenidate use among 8 th, 10 th, and 12
th grade students in the United States, 2001.  J Adolesc Health
2004, 35:501-504.
18. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM,
Penne MA: Nonmedical use of prescription stimulants in thePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Substance Abuse Treatment, Prevention, and Policy 2006, 1:15 http://www.substanceabusepolicy.com/content/1/1/15
Page 7 of 7
(page number not for citation purposes)
United States.  Drug and Alcohol Dependence  in press. February 15,
2006
19. Simoni-Wastila L, Strickler G: Risk factors associated with prob-
lem use of prescription drugs.  Am J Pub Health 2004, 94:266-268.
20. Website title   [http://www.oas.samhsa.gov/stimulantsNS.htm]
21. Babcock Q, Byrne T: Student perceptions of methylphenidate
abuse at a public liberal arts college.  J Am Coll Health 2000,
49:143-145.
22. Teter CJ, McCabe SE, Boyd CJ, Guthrie SK: Illicit methylphenidate
use in an undergraduate student sample: prevalence and risk
factors.  Pharmacotherapy 2003, 23:609-617.
23. Teter CJ, McCabe SE, Cranford JA, Boyd CJ, Guthrie SK: Prevalence
and motives for illicit use of prescription stimulants in an
undergraduate student sample.  J Am Coll Health 2005,
53:253-262.
24. Low KG, Gendaszek AE: Illicit use of psychostimulants among
college students: A preliminary study.  Psychol Health Med 2002,
7:283-287.
25. Barrett SP, Darredeua C, Bordy LE, Pihl RO: Characteristics of
methylphenidate misuse in a university student sample.  Can
J Psychiatry 2005, 50:457-461.
26. Coetzee M, Kaminer Y, Morales A: Megadose intranasal methyl-
phenidate (Ritalin) abuse in adult Attention Deficit Hyperac-
tivity Disorder.  Subst Abus 2002, 23:165-169.
27. Parran TV Jr, Jasinski DR: Intravenous methylphenidate abuse.
Prototype for prescription drug abuse.  Archives of Internal Med-
icine 1991, 151:781-783.
28. Meririnne E, Kankaampaa A, Seppala T: Rewarding properties of
methylphenidate: Sensitization by prior exposure to the
drug and effects of dopamine D1 – and D2 – receptor ago-
nists.  Pharmacol Exp Ther 2001, 298:539-550.
29. Julien RM: A Primer of Drug Action.  New York: Worth Publish-
ers; 2001. 
30. Volkow ND, Wang G-J, Fowler JS, Gatley SJ, Logan J, Ding Y-S, Hitze-
mann R, Pappas N: Dopamine transporter occupancies in the
human brain induced by therapeutic doses of oral methyl-
phenidate.  Am J Psychiatry 1998, 155:1325-1331.
31. Volkow ND, Swanson JM: Variables that affect the clinical use
and abuse of methylphenidate in the treatment of ADHD.
Am J Psychiatry 2003, 160:1909-1918.
32. Miller T, Leger MC: A very childish moral panic: Ritalin.  J Med
Humanit 2003, 24:9-33.
33. Substance Abuse and Mental Health Services Administra-
tion. Office of Applied Studies.  In Emergency Department Trends
for the Drug Abuse Warning Network, Final Estimates 1995–2002
DAWN Series: D-24, DHHS Publication No. (SMA) 03- Rockville,
MD; 2003. 
34. Website title   [http://www.drugs.com]
35. Ward S, Heyneman LE, Reittner P, Kazerooni EA, Godwin JD, Muller
NL: Talcosis associated with IV abuse of oral medications: CT
findings.  Am J Roentgenol 2000, 174:789-793.
36. Pentz MA, Bonnie RJ, Shopland DR: Integrating supply and
demand reduction strategies for drug abuse prevention.  Am
Behav Sci 1996, 39:897-910.
37. Website title   [http://www.natlalliance.org/prescription_drug.asp]
38. Website title   [http://www.nyu.edu/nyuhc/studydrugs/]
39. Website title   [http://www.ucc.vt.edu/stdysk/stdyhlp.html]